Agility Clinical, Inc.

agility-clinical.com

Agility Clinical is a unique consulting and contract research organization dedicated to working with virtual, small biopharma and device companies with a lean infrastructure. We put our expertise and passion to work helping small companies - particularly those involved with orphan drug development - to move forward and bring important new treatments to patients.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Medical

GT MOLECULAR, RAPIDLY EXPANDING MOLECULAR DIAGNOSTICS BIOTECH, LAUNCHES TWO HIGHLY SENSITIVE TESTS FOR THE DANGEROUS UK VARIANT OF SARS-COV-2

GT Molecular | January 13, 2021

news image

GT Molecular, a quickly extending sub-atomic diagnostics biotech, has dispatched two profoundly delicate tests for the risky UK Variant of SARS-CoV-2 (B.1.1.7). These tale examines expand upon GT Molecular's clinical foundation and technology for profoundly exact and solid qPCR and advanced PCR recognition of SARS-CoV-2 virus and are offered in two formats. The fee-for-service testing of wastewater for the presence of SARS-CoV-2 and the variations available for use furnishes n...

Read More

Cell and Gene Therapy

INTRAVACC ANNOUNCES ADDITIONAL FAVORABLE PRECLINICAL AND TOXICOLOGY DATA FOR AVACC 10®, AN INTRANASAL SARS-COV-2 CANDIDATE VACCINE

Intravacc | September 12, 2022

news image

Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced additional favorable preclinical and toxicology data for Avacc 10®, the company's SARS-CoV-2 intranasal candidate vaccine. These results demonstrate a reduction in upper respiratory tract viral load, broad cross protection against circulating variants of concern. and a good safety profile, allowing progression towards a phase I clinical study. ...

Read More

Research, Industry Outlook

BIGHAT BIOSCIENCES ANNOUNCES RESEARCH COLLABORATION WITH MERCK

BigHat Biosciences, Inc. | November 30, 2022

news image

BigHat Biosciences, Inc., a biotechnology company with a machine learning-guided antibody discovery and development platform, announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply the company’s technology to design candidates for up to three drug discovery programs. BigHat’s design platform, Milliner, integrates a high-speed characterization with ML technologies to engineer antibodies with more complex functions and better...

Read More

Industrial Impact

CLOVER SELECTED FOR INCLUSION ON THE HANG SENG COMPOSITE INDEX

Clover Biopharmaceuticals | February 25, 2022

news image

Clover Biopharmaceuticals, Ltd. a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that it has been selected for inclusion in the Hang Seng Composite Index as a constituent stock, effective March 7, 2022. Hang Seng Composite Index Hang Seng Small Cap (Investable) Index Hang Seng Healthcare Index Hang Seng Hong Kong-Listed Biotech Index ...

Read More
news image

Medical

GT MOLECULAR, RAPIDLY EXPANDING MOLECULAR DIAGNOSTICS BIOTECH, LAUNCHES TWO HIGHLY SENSITIVE TESTS FOR THE DANGEROUS UK VARIANT OF SARS-COV-2

GT Molecular | January 13, 2021

GT Molecular, a quickly extending sub-atomic diagnostics biotech, has dispatched two profoundly delicate tests for the risky UK Variant of SARS-CoV-2 (B.1.1.7). These tale examines expand upon GT Molecular's clinical foundation and technology for profoundly exact and solid qPCR and advanced PCR recognition of SARS-CoV-2 virus and are offered in two formats. The fee-for-service testing of wastewater for the presence of SARS-CoV-2 and the variations available for use furnishes n...

Read More
news image

Cell and Gene Therapy

INTRAVACC ANNOUNCES ADDITIONAL FAVORABLE PRECLINICAL AND TOXICOLOGY DATA FOR AVACC 10®, AN INTRANASAL SARS-COV-2 CANDIDATE VACCINE

Intravacc | September 12, 2022

Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced additional favorable preclinical and toxicology data for Avacc 10®, the company's SARS-CoV-2 intranasal candidate vaccine. These results demonstrate a reduction in upper respiratory tract viral load, broad cross protection against circulating variants of concern. and a good safety profile, allowing progression towards a phase I clinical study. ...

Read More
news image

Research, Industry Outlook

BIGHAT BIOSCIENCES ANNOUNCES RESEARCH COLLABORATION WITH MERCK

BigHat Biosciences, Inc. | November 30, 2022

BigHat Biosciences, Inc., a biotechnology company with a machine learning-guided antibody discovery and development platform, announced a collaboration with Merck, known as MSD outside of the United States and Canada, to apply the company’s technology to design candidates for up to three drug discovery programs. BigHat’s design platform, Milliner, integrates a high-speed characterization with ML technologies to engineer antibodies with more complex functions and better...

Read More
news image

Industrial Impact

CLOVER SELECTED FOR INCLUSION ON THE HANG SENG COMPOSITE INDEX

Clover Biopharmaceuticals | February 25, 2022

Clover Biopharmaceuticals, Ltd. a global clinical-stage biotechnology company developing novel vaccines and biologic therapeutic candidates, today announced that it has been selected for inclusion in the Hang Seng Composite Index as a constituent stock, effective March 7, 2022. Hang Seng Composite Index Hang Seng Small Cap (Investable) Index Hang Seng Healthcare Index Hang Seng Hong Kong-Listed Biotech Index ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us